Referencias:
Baden, L. R., Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., . . . Zaks, T. (2021). Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. New England Journal of Medicine, 384(5), 403-416. doi:10.1056/nejmoa2035389
Halperin, S. A., Ye, L., Mackinnon-Cameron, D., Smith, B., Cahn, P. E., Ruiz-Palacios, G. M., . . . Zubkova, T. (2021). Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: An international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. The Lancet. doi:10.1016/s0140-6736(21)02753-7
